Promising CAR-T trial for blood cancer withdrawn before starting
NCT ID NCT07093086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei Yanda Ludaopei Hospital
Hebei, China
-
Tongji Hospital of Tongji University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma